Repository logo
 
Publication

Serum dipeptidyl peptidase 4: a predictor of disease activity and prognosis in inflammatory bowel disease

2020-11Journal article Restricted access
Simple item page
dc.contributor.authorPinto-Lopes, Pedro
dc.contributor.authorAfonso, Joana
dc.contributor.authorPinto-Lopes, Rui
dc.contributor.authorRocha, Catia
dc.contributor.authorLago, Paula
dc.contributor.authorGoncalves, Raquel
dc.contributor.authorSousa, Helena Tavares
dc.contributor.authorMacedo, Guilherme
dc.contributor.authorDias, Claudia Camila
dc.contributor.authorMagro, Fernando
dc.date.accessioned2021-06-18T16:25:49Z
dc.date.available2021-06-18T16:25:49Z
dc.date.issued2020-11
dc.description.abstractBackground: Serum dipeptidyl peptidase 4 (DPP-4) has drawn particular interest as a biomarker in inflammatory bowel disease (IBD), as this protease inactivates several peptides that participate in the inflammatory cascade. Methods: Two prospectively recruited cohorts consisting of 195 patients (101 had Crohn’s disease [CD] and 94 had ulcerative colitis [UC]) were evaluated using clinical indexes and followed up to assess for treatment escalation. Sixty-eight patients underwent endoscopic evaluation at baseline. In the second cohort of 46 biologically treated patients, treatment response was assessed. Serum DPP-4, C-reactive protein (CRP), and fecal calprotectin levels were quantified at baseline and during follow-up. Results: Median DPP-4 levels were significantly lower in active IBD patients when compared with remitters (CD: 1043 [831–1412] vs 1589 [1255–1956] ng/mL; P < 0.001; UC: 1317 [1058–1718] vs 1798 [1329–2305] ng/mL; P = 0.001) and healthy controls (2175 [1875–3371] ng/mL). In fact, DPP-4 was able to distinguish clinical and endoscopic activity from remission, with areas under the curve (AUC) of 0.81/0.93 (CD) and 0.71/0.79 (UC), along with the need for treatment escalation, with comparable AUCs of 0.79 (CD) and 0.77 (UC). Furthermore, DPP-4 levels were higher in responders to treatment and more pronounced among UC (1467 [1301–1641] vs 1211 [1011–1448] ng/mL; P < 0.001) than CD patients (1385 [1185–1592] vs 1134 [975–1469] ng/mL; P = 0.015). Conclusions: Our results suggest that serum DPP-4 can be used as a noninvasive biomarker of IBD activity and biological treatment response and a predictor of treatment escalation, particularly when combined with other biomarkers.
dc.description.sponsorshipPortuguese IBD Study Group (Grupo de Estudo da Doenca Inflamatoria Intestinal [GEDII])
dc.description.sponsorshipJanssen-Cilag Pharmaceuticals
dc.description.sponsorshipFundacao para a Ciencia e Tecnologia (FCT) Portugal [PDE/BDE/114583/2016]
dc.description.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.1093/ibd/izz319
dc.identifier.issn1078-0998
dc.identifier.urihttp://hdl.handle.net/10400.1/15679
dc.language.isoeng
dc.peerreviewedyes
dc.publisherOxford University Press
dc.subjectBiomarkers
dc.subjectDipeptidyl peptidase 4
dc.subjectInflammatory bowel disease
dc.subject.otherGastroenterology & Hepatology
dc.titleSerum dipeptidyl peptidase 4: a predictor of disease activity and prognosis in inflammatory bowel disease
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage1719
oaire.citation.issue11
oaire.citation.startPage1707
oaire.citation.titleInflammatory Bowel Diseases
oaire.citation.volume26
person.familyNameSousa
person.givenNameHelena Tavares
person.identifier.ciencia-idCF1F-1163-1C4A
person.identifier.orcid0000-0002-6626-205X
rcaap.rightsrestrictedAccess
rcaap.typearticle
relation.isAuthorOfPublication6b1d11dd-486f-4fb3-b41f-02e1cf6a5c2e
relation.isAuthorOfPublication.latestForDiscovery6b1d11dd-486f-4fb3-b41f-02e1cf6a5c2e

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
10.1093@ibd@izz319.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)
ULS2-Artigos (em revistas ou actas indexadas)